Non-steroidal anti-in‰ammatory drugs (NSAIDs) are widely used to treat in‰ammatory diseases including rheumatoid arthritis and gout. The anti-in‰ammatory action of NSAIDs is due to the inhibition of prostaglandin synthesis by preventing cyclooxygenase (COX) activity of prostaglandin H synthase (PGS). However, administration of NSAIDs causes gastrointestinal mucosal lesions and a decrease of granulocytes as side eŠects. PGS catalyzes two distinct enzyme reactions: (1) bis-dioxygenation of arachidonic acid catalyzed by COX activity of PGS to form PGG 2 ; and (2) reduction of the hydroperoxide group in PGG 2 by PGS hydroperoxidase. Most NSAID are oxidized by peroxidases to produce NSAID radicals that damage biological components such as lipids and enzymes. Indomethacin, phenylbutazone, and piroxicam are more toxic under aerobic conditions than anaerobic conditions during the interaction with peroxidase. We discuss the contribution of peroxidases in the formation of gastrointestinal mucosal lesions induced by NSAIDs.
This process involves two intermediates in which one oxidizing equivalent is stored as a ferryl heme and a second oxidizing equivalent is located on either the porphyrin in Intermediate I or tyrosine 385 Intermediate II. The Fe 4＋ -oxo species is reduced back to the ferric resting state by reducing cosubstrates (NSAIDs). ROOH: alkylhydroperoxide, Tyr: tyrosin, AA: arachidonic acid, PGG2: prostaglandin G2. 
